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Abstract
The β3-adrenergic receptor (β3AR) is an essential regulator of metabolic and endocrine functions. A
major cellular and clinically significant consequence of β3AR activation is the substantial elevation
in interleukin-6 (IL-6) levels. Although the β3AR-dependent regulation of IL-6 expression is well
established, the cellular pathways underlying this regulation have not been characterized. Using a
novel method of homogenous reporters, we assessed the pattern of activation of 43 transcription
factors in response to the specific β3AR agonist CL316243 in adipocytes, cells that exhibit the highest
expression of β3ARs. We observed a unique and robust activation of the CRE-response element,
suggesting that IL-6 transcription is regulated via the Gs-protein/cAMP/protein kinase A (PKA) but
not nuclear factor kappa B (NF-κB) pathway. However, pretreatment of adipocytes with
pharmacologic inhibitors of PKA pathway failed to block β3AR-mediated IL-6 up-regulation.
Additionally, stimulation of adipocytes with the exchange protein directly activated by cAMP (Epac)
agonist did not induce IL-6 expression. Instead, the β3AR-mediated transcription of IL-6 required
activation of both the p38 and PKC pathways. Western blot analysis further showed that transcription
factors CREB and ATF-2 but not ATF-1 were activated in a p38- and PKC-dependent manner.
Collectively, our results suggest that while stimulation of the β3AR leads to a specific activation of
CRE-dependent transcription, there are several independent cellular pathways that converge at the
level of CRE-response element activation, and in the case of IL-6 this activation is mediated by p38
and PKC but not PKA pathways.
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Interleukin-6 (IL-6) is a pleiotropic cytokine that modulates immune response, inflammation,
nervous, hematopoietic, and endocrine systems (Kamimura et al., 2003; Kishimoto, 2005).
Although IL-6 has a widespread tissue distribution, previous reports have indicated that up to
30% of circulating IL-6 is derived from adipose tissue (Fried et al., 1998; Mohamed-Ali et al.,
1997). Consistent with these reports, plasma IL-6 levels are markedly elevated in obese subjects
(Vgontzas et al., 1997). Obesity is closely associated with chronic low-grade inflammation
characterized by abnormal production of cytokines and acute phase proteins (Hotamisligil,
2006; Wellen and Hotamisligil, 2005). The inflammatory response that emerges in the presence
of obesity seems to be triggered by and predominantly reside in adipose tissue. Additionally,
the production of IL-6 is well documented in different adipose tissues and adipocyte models
(Burysek and Houstek, 1997; Fain et al., 2004; Hoch et al., 2008; Mohamed-Ali et al., 2001;
Path et al., 2001; Skurk et al., 2007; Vicennati et al., 2002).
Both white (WAT) and brown (BAT) adipose tissues are innervated by sympathetic nervous
system (SNS) (Fliers et al., 2003; Slavin and Ballard, 1978; Wirsen and Hamberger, 1967).
Although sympathetic innervation is less abundant in WAT than in BAT, norepinephrine
turnover in WAT can be significant in the immediate vicinity of nerve terminals, particularly
in response to stress (Bamshad et al., 1998; Collins et al., 2004). In rodents SNS activation
during stress has been associated with elevated plasma IL-6 levels (Takaki et al., 1994; Zhou
et al., 1993). Similarly, in humans a positive correlation has been observed between exercise-
induced peak plasma epinephrine or norepinephrine and IL-6 levels (Papanicolaou et al.,
1996). Epinephrine and norepinephrine regulate IL-6 release from adipocytes predominantly
via activation of β-adrenergic receptors (βARs). In vitro, administration of norepinephrine, the
general βAR agonist isoproterenol, or the selective β3AR agonist CGP-12117 stimulated IL-6
expression in murine brown adipocytes (Burysek and Houstek, 1997), and isoproterenol
elevated IL-6 production in human breast adipocytes (Path et al., 2001). In vivo, administration
of β2 or β3 agonists in mice or infusion of isoproterenol in human volunteers resulted in
heightened plasma IL-6 concentrations (Mohamed-Ali et al., 2001). Although β3AR-
dependent regulation of IL-6 expression is well established, the intracellular signaling
pathways underlying this regulation have not been characterized.
Activation of the β3AR by epinephrine, norepinephrine, or specific agonists typically results
in the Gs-dependent activation of adenylate cyclase, increases in intracellular cAMP, and
stimulation of protein kinase A (PKA) (Guan et al., 1995; Lindquist et al., 2000; Soeder et al.,
1999). PKA, in turn, regulates expression of various genes via phosphorylation of the
transcription factor cAMP-responsive element binding protein (CREB) which binds to cAMP-
responsive element (CRE) sites in the promoter region of cAMP-responsive genes (Rockman
et al., 2002). Recently, cAMP has been shown to activate not only PKA but also a class of
cyclic nucleotide-gated (CNG) cation channels and a small family of guanine nucleotide
exchange factors (GEFs) known as exchange proteins directly activated by cAMP (Epacs) (de
Rooij et al., 1998; Kawasaki et al., 1998b).
New layers of complexity have been added to the field of β3AR signaling with the discovery
that β3ARs couple to Gi as well as Gs. In adipocytes, stimulation of the β3AR activates the
extracellular signal-regulated kinases 1 and 2 (ERK1/2) via the Gi-dependent pathway (Cao et
al., 2000; Gerhardt et al., 1999; Soeder et al., 1999). However, discrepant reports from other
groups suggest that β3AR-dependent ERK1/2 activation is mediated via the Gs/PKA pathway
(Lindquist et al., 2000; Mizuno et al., 1999). In addition to ERK1/2, activation of β3ARs in
adipocytes has been shown to stimulate another mitogen-activated protein kinase (MAPK) p38
through the classical Gs- and PKA-dependent pathway (Cao et al., 2001; Moule and Denton,
1998), although an obligatory role of PKA in p38 phosphorylation was not confirmed in another
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work (Mizuno et al., 2002). Finally, activation of β3ARs leads to stimulation of one more major
family of signaling enzymes- protein kinases C (PKCs). It has been demonstrated that β3AR
agonists increase glucose uptake in brown adipocytes stimulating conventional and novel PKCs
(Chernogubova et al., 2004). Thus, β3ARs exhibit a dynamic capacity to stimulate divergent
signaling pathways.
To elucidate the signaling pathways controlling IL-6 production in white adipocytes, we
employed a novel method of homogenous reporters (Romanov et al., 2008) and assessed the
activation pattern of 43 transcription factors in response to the β3AR-specific agonist
CL316243. We observed a unique and robust activation of the CRE-response element, but not
NF-κB which is a pivotal regulator of pro-inflammatory cytokine expression (Baldwin,
1996). CRE activation suggested regulation of IL-6 transcription via Gs/cAMP/PKA activity.
However, subsequent experiments demonstrated that IL-6 expression is not mediated through
PKA or NF-κB pathways, but instead requires activation of p38- and PKC-dependent signaling
mechanisms.
2. Materials and Methods
2.1. Cell culture
The C3H10T1/2, 3T3-L1, and HEK 293 cells were obtained from American Tissue Culture
Collection Center (Rockville, MD). Cells were grown in DMEM (Sigma, St Louis, MO)
supplemented with 10% heat-inactivated FBS (Sigma), 2mM L-glutamine (Gibco, Carlsbad,
CA), and 1x penicillin/streptomycin (Gibco) under a humidified atmosphere with 5% CO2 at
37°C. 3T3-L1 fibroblast cells were treated with 0.5 mM IBMX (Sigma), 1 μM dexamethasone
(Sigma), and 10 μg/ml insulin (Sigma) to initiate adipogenesis as described previously (Mizuno
et al., 1999). C3H10T1/2 adipogenesis was induced by incubating cells in growth media
containing 1 μM dexamethasone, 0.5 mM IBMX, 1 μM rosiglitazone, and 10 μg/ml insulin for
2 days, after which cells were allowed to differentiate in growth media with two more boosts
of 1 μM rosiglitazone and 10 μg/ml insulin. After more than 90% of cells became differentiated,
the media containing inducers of differentiation was replaced with growth medium without
inducers, and cells were maintained for two more days in culture. Then adipocytes were treated
with various reagents.
2.2. Factorial homogenous reporter system
The mouse pluripotent fibroblasts C3H10T1/2 were plated at subconfluent density in 6-well
plates and then transfected the next day with the Factorial reporter library as described
previously (Romanov et al., 2008). The C3H10T1/2 cells were selected because we found that
they provide a unique fibroblast cell system that will continue to differentiate into adipocytes
after transfection, a critical step required for the Factorial application. After appropriate
adipocyte differentiation, the cells were stimulated with various reagents, total cellular RNA
was extracted and processed according to the Factorial detection protocol and quantified as
described previously (Romanov et al., 2008).
2.3. Drugs and treatment
CL316243, ICI 118,551, Betaxolol, SR59230A, RO31-8220, PTX, and 8CPT-2’-O-Me-cAMP
were obtained from Tocris Cookson, Ellisville, MI. NBD peptide, MG-132, U0126, and
SB203580 were purchased from Biomol, Plymouth Meeting, PA. CTX was bought from
Calbiochem, La Jolla, CA. An aliquot of each drug solution was added to the medium, and the
final concentration of the vehicle in the medium was adjusted to 0.1% (v/v). The control
medium contained the same amount of the vehicle. For inhibitor experiments, cells were
pretreated with the indicated drug for 1 h prior. Dose-response curves were established for the
agonist and antagonist. Doses within one log unit of the ED50 or ID50 were used for all in
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vitro experiments. The effectiveness of the chosen inhibitor doses was confirmed in our
previous report (Tan et al., 2007).
2.4. Detection of IL-6 by real-time PCR and ELISA
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA). Prior to reverse
transcription, RNA was treated with 2 units of TURBO DNase I (Ambion, Austin, TX) at 37°
C for 30 min. Reverse transcription was performed using Superscript III (Carlsbad, CA,
Invitrogen) according to the manufacturer’s instructions. IL-6 transcripts were quantified by
real-time PCR using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA)
in an ABI PRISM 7000 Sequence Detection System. The expression of cytokine mRNAs was
normalized to the relative abundance of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Fold induction was calculated using the 2−ΔΔCt method (Livak and Schmittgen,
2001). Experiments were performed in quadruplicate. IL-6 protein was determined in the
culture supernatant of adipocytes using ELISA kits (R&D Systems, Minneapolis, MN). ELISA
was performed according to the manufacturer’s instructions. Experiments were performed in
triplicate.
2.5. Plasmids and transfections
Reporter vectors containing specific cis-acting DNA sequence fused to secreted alkaline
phosphatase (SEAP), pCRE-SEAP, pAP-1-SEAP, pC/EBPβ-SEAP, pNF-κB-SEAP and
pETS-SEAP, were purchased from Clontech, Inc. (Palo Alto, CA). Mouse β3-AR clone
(GB#BC132000) was purchased from I.M.A.G.E. Consortium Collection (Open Biosystems,
Huntsville, AL) and subcloned into pCMV-SPORT6 expression vector (Invitrogen, Carlsbad,
CA). The 3rd exon of the clone (nucleotides 1239 to 1327) has been replaced with the PCR
amplified cDNA fragment corresponding to 3rd exon of the major β3-AR isoform NM_013462
(nucleotides 1975 to 2042). The functional activity of the clone has been confirmed in
transfection experiments. HEK 293 cells were transfected with Effectene transfection reagent
(Qiagen) according to the manufacturer’s instructions. For normalization of transfection
efficiency, cells were co-transfected with a β-galactosidase plasmid (Clontech). Cell
stimulation experiments were performed 24 h after transfection. Experiments were performed
in triplicate.
2.6. SEAP activity assay
The culture medium was changed to remove the accumulated SEAP prior to treatment of cells
with CL316243. The cells were incubated with CL316243 for 6, 12 or 24 h. Culture medium
was collected and subjected to SEAP activity assays. The SEAP activity in the culture medium
was measured with a Phospha-Light assay kit (Tropix, Foster City, CA), according to the
instructions of the manufacturer. Experiments were performed in triplicate.
2.7. Western blot analyses
Cells were lysed using cell lysis buffer containing phosphatase inhibitors (Cell Signaling
Technologies, Danvers, MA). The amount of protein in the cell lysates were quantified using
the BCA Protein Assay Reagent (Pierce, Rockford, IL). Proteins were resolved on 12% sodium
dodecyl sulfate (SDS) NuPAGE Novex Gels (Invitrogen, Carlsbad, CA). Following gel
electrophoresis, proteins were transferred to nitrocellulose membranes (Amersham, Piscatawy,
NJ). Membranes were blocked with 5% non-fat milk at room temperature for 1 h and then
probed with the specific antibodies at 4°C overnight. Protein expression was determined with
the specific primary antibodies according to the manufacturer’s instructions. Antibodies to p-
p38, pPKCs, pATF-2 and pCREB were obtained from Cell Signaling Technologies, Danvers,
MA, and antibodies to p-PKCε were received from Santa Cruz Biotechnology, Santa Cruz,
CA. The pCREB antibody also detects the pATF-1 at a different size. β-actin was used as the
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loading control. Antibodies were detected with corresponding horseradish peroxidase-linked
secondary antibodies. Blots were developed using Enhanced Chemiluminescent (ECL) reagent
(Perkin Elmer, Waltham, MA) and signals captured using the ImageQuant ECL system
(Amersham). Experiments were performed in triplicate.
2.8. Statistical analysis
Statistical significance was determined by performing an analysis of variance (ANOVA)
followed by Bonferroni test. Data are expressed as mean ± SEM. Differences were considered
significant if P < 0.05.
3. Results
3.1. β3AR activation leads to IL-6 increase in white adipocytes
We first sought to confirm that β3AR stimulation can modulate IL-6 mRNA expression in the
3T3-L1 adipocyte cell model (Green and Kehinde, 1976). 3T3-L1 adipocytes were treated with
CL316243, a specific β3 agonist (Bloom et al., 1992), and real-time quantitative PCR was used
to quantify the level of mRNA transcripts present. Treatment of 3T3-L1 cells with CL316243
(1 μM) resulted in about 30-fold increase in IL-6 transcripts, when compared to untreated cells
(Fig. 1a). In line with previously reported correlation between up-regulation of IL-6 mRNA
and protein secretion (Burysek and Houstek, 1997; Path et al., 2001), this increase in IL-6
mRNA expression was accompanied by a 3.5- and 4.8-fold increase in IL-6 protein secretion
by 24 and 48 h, respectively (Fig. 1b). Similarly, an up-regulation of IL-6 expression was also
observed in the murine white adipocytes C3H10T1/2 (results not shown). The CL316243-
induced up-regulation of IL-6 transcripts was blocked by the specific β3AR antagonist
SR59230A (1 μM), but not by the specific β1AR antagonist betaxolol (0.5 μM) or the specific
β2AR antagonist ICI118,551 (0.5 μM) (Fig. 1a). These results indicate that β3AR stimulation
leads to a significant up-regulation of IL-6 expression in white adipocytes.
3.2. β3AR-mediated IL-6 expression is PKA- and Epac- independent
To identify the regulatory pathways involved in β3AR-mediated signaling, we used a recently
described homogeneous reporter system termed Factorial (Romanov et al., 2008). The system
comprises 43 cis-regulatory reporter transcription units enabling simultaneous functional
profiling of multiple transcription factors present in the cell. We found that of all the Factorial
reporters, the CRE reporter was the only one whose activity was strongly induced (12-fold
induction) by CL316243 (1 μM) in C3H10T1/2 adipocytes (Fig. 2a). Activation of the CRE
reporter in the homogenous reporter experiment together with the presence of a functional CRE
element in the promoter region of IL-6 (Ammit et al., 2002; Edwards et al., 2007; Ray et al.,
1988) led to the expectation that the cAMP/PKA/CREB cascade underlies β3AR-mediated
IL-6 regulation. Surprisingly, however, stimulation of the CRE reporter in adipocytes by
CL316243 was not inhibited by the PKA inhibitor H89 (10 μM) (Fig. 2a). Furthermore, IL-6
mRNA expression was not blocked in 3T3-L1 cells pretreated with the PKA inhibitors H89 or
KT5720 (Fig. 2b), suggesting that the β3AR-dependent signaling pathway(s) leading to IL-6
up-regulation are distinct from the cAMP/PKA regulatory pathway.
We further examined the possibility that cAMP could activate IL-6 production through the
PKA-independent Epac (guanine nucleotide exchange factors directly activated by cAMP)
pathway (de Rooij et al., 1998; Kawasaki et al., 1998b). Epac proteins bind cAMP with high
affinity and activate the Ras superfamily small GPTases Rap1 and Rap2. To determine if Epac
activation results in IL-6 production, 3T3-L1 cells were treated with the Epac agonist, 8CPT-2’-
O-Me-cAMP (CPTOMe, 10 μM), and the level of IL-6 mRNA measured by real-time
quantitative PCR (Fig. 2c). Treatment of cells with CPTOMe failed to promote increased IL-6
mRNA levels. However, similar to previous reports, treatment of 3T3-L1 cells with cholera
Tchivileva et al. Page 5













toxin (CTX), an activator of Gs proteins (Cassel and Selinger, 1977), did lead to a 16-fold
increase in IL-6 mRNA levels (Fig. 2c). Together, these data indicate that β3AR-mediated IL-6
production in white adipocytes depends on CRE activation but not PKA or Epac activation.
3.3. β3AR-mediated IL-6 expression is NF-κB-independent
Transcription factor NF-κB is a pivotal regulator of inflammation and has been shown to play
a central role in the transcriptional regulation of pro-inflammatory cytokines (Baldwin,
1996). Therefore, we sought to investigate whether NF-κB stimulation is required for β3AR-
mediated IL-6 expression. In a homogenous reporter system, NF-κB reporter activity was not
affected by CL316243 (1 μM) treatment, though it was strongly induced by TNFα (10 ng/ml)
which served as a positive control for NF-κB activation (Fig. 3a).
As the homogenous reporter assay results did not suggest a contribution of NF-κB in
CL316243-dependent IL-6 up-regulation, we confirmed this conclusion by independent
approaches. NF-κB activity can be inhibited using either NEMO binding peptide (NBD), which
binds to and inactivates IKKγ thereby blocking the phosphorylation and degradation of IκB
(May et al., 2000; Yamaoka et al., 1998), or MG-132, a proteosome inhibitor (Fenteany et al.,
1995; Myung et al., 2001). Pre-treatment of 3T3-L1 cells with NBD (100 μM) or MG-132 (25
and 50 μM) prior to β3AR stimulation with CL316243 (1 μM) did not block IL-6 up-regulation
(Fig. 3b) confirming the mechanism is NF-κB-independent.
In agreement with these results and data from homogenous reporter assay, human embryonic
kidney cell line 293 (HEK 293) co-transfected with the pNF-κB-SEAP reporter vector and
β3AR expression construct did not show significant changes in SEAP reporter activity
following CL316243 (1 μM) treatment (Fig. 3c). Thus, all these experiments strongly indicate
that β3AR stimulation does not result in NF-κB activation.
3.4. Role of MAPK pathways in β3AR-mediated IL-6 expression
It has been reported that β3ARs can activate ERK1/2 and p38 MAPK cascades through
interchangeable coupling to both Gi and Gs (Collins et al., 2004). Although findings from
various studies differ, β3AR coupling with Gi proteins has been implicated in phosphorylation
of ERK1/2 (Cao et al., 2000; Gerhardt et al., 1999; Robidoux et al., 2006; Soeder et al.,
1999). We used pertussis toxin (PTX), which ADP-ribosylates and inactivates Gi proteins, to
test the plausible contribution of this Gi-mediated pathway to β3AR-mediated IL-6 production.
The CL316243-induced IL-6 mRNA up-regulation was not inhibited in cells pretreated with
the PTX (Fig. 4a), excluding the role of Gi-dependent signaling in the regulation of IL-6
expression.
We next examined whether inhibition of the MAPK pathways could block the β3AR-dependent
IL-6 production. Pretreatment of 3T3-L1 cells with the p38 inhibitor SB203580 (5-10 μM)
blocked the CL316243-induced increase in IL-6 mRNA level (Fig. 4b). In contrast,
pretreatment with ERK inhibitor U0126 (10 μM) had no effect on CL316243-induced IL-6
expression (Fig. 4b). In the homogenous reporter assay, activation of the CRE reporter by
CL316243 was also blocked by pretreatment with SB203580 (10 μM; Fig. 4c). Additionally,
p38 phosphorylation following CL316243 treatment was observed in cell lysates by Western
blot analyses (Fig. 4d). Taken together, these results indicate that while no contribution of
Gi-dependent ERK1/2 stimulation was observed, p38 activation is required for β3AR-mediated
IL-6 production.
3.5. Role of the PKC pathway in β3AR-mediated IL-6 expression
Previous work has demonstrated that protein kinases C (PKCs) are essential for β3AR-mediated
glucose uptake regulation (Chernogubova et al., 2004). Thus, we sought to determine the effect
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of PKC inhibition on β3AR-mediated IL-6 production using the specific PKC inhibitor
RO31-8220 which blocks conventional (α, β, γ) and novel (ε and θ) PKC isoforms (Wilkinson
et al., 1993; Yuan et al., 2002). Pretreatment with RO31-8220 (1 and 10 μM) completely
inhibited CL316243-induced IL-6 mRNA expression in 3T3-L1 cells (Fig. 5a) and
significantly inhibited CL316243-mediated activation of the CRE reporter in the homogenous
reporter assay (Fig. 5b). Additionally, CL316243-mediated phosphorylation of several PKC
subtypes was detected applying an antibody specific for a panel of PKCs (α, βI, βII, δ, ε, and
η) phosphorylated at C-terminal residue homologous to serine 660 of PKCβII. In a subsequent
attempt to identify individual PKC isoforms activated by CL316243 treatment,
phosphorylation of PKC α/βII, θ, and ε was observed with the use of isoform-specific antibodies
(Fig. 5c). These findings indicate that conventional and novel isoforms of PKC play a
significant role in β3AR-mediated IL-6 expression.
3.6. Stimulation of β3AR leads to the phosphorylation of transcription factors CREB and
ATF-2
To determine transcription factors that mediate β3AR-dependent IL-6 expression, the
transcription factors which bind to the CRE-response element were investigated. First, to
confirm the results of the homogeneous reporter assay, a pCRE-SEAP reporter vector with the
CRE-response element was co-transfected into HEK293 cells with a β3AR expression
construct (Fig.6a). Cells were treated with CL316243, and SEAP activity was measured over
a 24-hour period. In agreement with the initial screening results, we observed a 5- to 6-fold
increase in CRE-dependent SEAP expression (Fig. 6a). To confirm that other transcription
factors most commonly associated with activation of PKC or p38 pathways are not activated
in response to β3AR stimulation (Buchwalter et al., 2004;Isakov and Altman, 2002;Trautwein
et al., 1993), analogues experiments were conducted with pAP-1-SEAP, pC/EBPβ-SEAP, and
pETS-SEAP reporter vectors. Again, in full agreement with the homogeneous reporter assay,
no significant differences in AP-1, C/EBPβ or ETS activities were found (Fig. 6b-d).
Transcription factors that specifically recognize the CRE-response element include the CREB/
ATF family (Hai and Hartman, 2001). We examined the phosphorylation states of CREB,
ATF-1, and ATF-2 transcription factors in 3T3-L1 adipocytes. An increased phosphorylation
of CREB, ATF-1, and ATF-2 was observed following CL316243 treatment (Fig. 7a).
Pretreatment of cells with the p38 inhibitor SB203580 (10 μM) remarkably reduced the
phosphorylation of both CREB and ATF-2, while administration of the PKC inhibitor
RO31-8220 (10 μM) decreased reduced phosphorylation of ATF-2 only (Fig. 7b). In contrast,
the phosphorylation of ATF-1 was unaffected by either SB203580 or RO31-8220. Thus, our
results suggest that the β3AR-dependent up-regulation of IL-6 transcription in adipocytes is
mediated by the transcription factors CREB and ATF-2.
4. Discussion
Activation of β3ARs in adipocytes and adipose tissue results in increased production of the
proinflammatory cytokine IL-6 (Burysek and Houstek, 1997; Mohamed-Ali et al., 2001; Path
et al., 2001). In the present study, we elucidated the signaling pathways underlying β3AR-
mediated regulation of IL-6 production in white adipocytes. In view of previous reports that
circulating IL-6 concentrations are elevated in obesity and that adipose tissue releases up to
30% of total IL-6 in the circulation (Fried et al., 1998; Mohamed-Ali et al., 1997; Vgontzas et
al., 1997), the molecular mechanisms contributing to enhanced production of this pro-
inflammatory cytokine may play an active role in generating low grade chronic inflammation
in obesity.
Here, we demonstrated that β3AR stimulation in white adipocytes dramatically increases both
mRNA and protein levels of IL-6 (30- and 5-fold, respectively). Adrenergic regulation of IL-6
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release has been reported in several other cell types, including macrophages (Tan et al.,
2007), hepatocytes (Jung et al., 2000), astrocytes (Norris and Benveniste, 1993), cardiac
fibroblasts (Yin et al., 2006), and endothelial cells (Gornikiewicz et al., 2000), although the
relative contribution of these tissues to circulating IL-6 concentrations is unknown. Adipose
tissue is innervated by postganglionic sympathetic nerves releasing norepinephrine, which
promote increased IL-6 levels in humans and animal models (Papanicolaou et al., 1996; Takaki
et al., 1994; Zhou et al., 1993). Thus, elevated systemic concentrations of IL-6 associated with
obesity could be related to higher SNS activity as well as increased adipose tissue mass in
obese subjects (Tentolouris et al., 2006).
To examine the transcriptional pathways involved in β3AR-mediated signaling, we utilized a
novel homogeneous reporter system (Romanov et al., 2008) enabling quantitative assessment
of multiple transcription factor activities in a eukaryotic cell. The robust activation of a single
CRE reporter along with the presence of a functional CRE element in the promoter region of
IL-6 (Ammit et al., 2002; Edwards et al., 2007; Ray et al., 1988), suggested that the cAMP/
PKA/CREB cascade underlies β3AR-mediated IL-6 production. Nevertheless, specific PKA
inhibitors failed to block either the IL-6 mRNA up-regulation induced by CL316243 in
adipocytes or the CRE activation in the homogenous reporter assay. Thus, our findings suggest
that the signaling mechanisms required for β3AR-mediated IL-6 production do not involve the
PKA pathway.
PKAs were considered to be the major effectors of cAMP until the recent discovery of Epacs,
exchange proteins directly activated by cAMP, which have been shown to activate the small
G proteins Rap1 and Rap2 (de Rooij et al., 1998; Kawasaki et al., 1998b). Stimulation of the
β2AR has been reported to induce PKA-independent cell adhesion through Epac and Rap1
(de Rooij et al., 1998). Epac activation produces an inhibitory effect on PKB phosphorylation
in rat white adipocytes (Zmuda-Trzebiatowska et al., 2007) while does not affect glucose
uptake in brown adipocytes (Chernogubova et al., 2004). Using the Epac-specific agonist
CPTOMe, we found no evidence for involvement of an Epac pathway in activation of IL-6
release in our experiments, although CTX treatment significantly elevated IL-6 mRNA
expression. These results suggest that β3AR-induced IL-6 production could be mediated by a
novel cAMP pathway through PKA- and Epac-independent mechanism. Indeed, several
atypical cAMP binding proteins have been described, including the cAMP receptor which
regulates development in Dictyostelium discoideum (Klein et al., 1988) and cyclic nucleotide
gated channels from olfactory neurons (Goulding et al., 1992). Whether atypical cAMP
pathways are involved in IL-6 secretion in adipocytes still needs further investigation.
Interestingly, β3AR-mediated IL-6 production was also independent from another pivotal
regulator of cytokine expression, NF-κB (Baldwin, 1996). The PKA- and NF-κB-independent
nature of β3AR-mediated IL-6 expression in adipocytes is in line with similar reports which
have been recently published regarding β2AR-mediated cytokine production. Secretion of IL-6
after β2AR stimulation is PKA-independent and p38-driven in mouse cardiac fibroblasts (Yin
et al., 2006), while β2AR-mediated release of IL-6 and IL-1β is PKA- and NF-κB-independent
in macrophages (Tan et al., 2007).
It has been reported that β3ARs can interchangeably couple to both Gs and Gi and activate
ERK1/2 via Gi-dependent mechanism in adipocytes (Gerhardt et al., 1999; Soeder et al.,
1999). Unlike β2AR, the β3AR doesn’t require receptor phosphorylation and, instead, recruits
c-Src kinases for ERK activation in PKA-independent manner (Cao et al., 2000; Robidoux et
al., 2006). In contrast, results from other groups argue that β3AR-mediated phosphorylation of
ERK1/2 is Gs- and PKA-dependent (Lindquist et al., 2000; Mizuno et al., 1999; Mizuno et al.,
2000). β3AR signaling is further complicated by alternative splicing of the gene. Two splice
variants, β3a and β3bARs that differ only in their C-termini (Evans et al., 1999), also display
differences in their signaling properties. The β3aAR couples only with Gs, probably due to
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localization in caveolae (Sato et al., 2007), whereas the β3bAR couples with Gs and Gi
(Hutchinson et al., 2002). Together, these reports indicate that β3AR may activate different
signaling mechanisms in different cell systems (white or brown adipocytes, cell lines or primary
cultures). We observed in white adipocyte cell lines that β3AR-mediated IL-6 expression is
Gi- and ERK1/2-independent, but instead is up-regulated by p38 MAPK and PKC pathways
(Fig. 8).
Next, we found that conventional PKCs (α/βII) and novel PKCs (θ and ε) are activated by
CL316243 in adipocytes. Our results are in line with previous work showing that β3AR agonists
increase glucose uptake in brown adipocytes via conventional and novel PKCs (Chernogubova
et al., 2004). Furthermore, up-regulation of IL-6 in a PKA-independent but PKC- and p38-
dependent manner has been previously reported for various G-protein-coupled receptors
(GPCR) in other types of cells, such as P2Y receptors in microglia (Shigemoto-Mogami et al.,
2001) and corticotropin-releasing factor receptor 2β in smooth muscle cells (Kageyama and
Suda, 2003) as well as under inflammatory conditions in astrocytes (Norris et al., 1994). Further
studies are needed to elucidate the exact mechanism of PKC activation by β3AR and its relation
to p38. As PKCs are known to be downstream effectors of phosphatidylinositol 3-kinase (PI3K)
(Standaert et al., 1997), it is plausible that PKCs activated by β3ARs in adipocytes are
downstream of PI3K and not directly activated by elevated cAMP. Interestingly, while p38
and PKC pathways appear to be distinct, our findings reveal that inhibition of either one of
them can completely abolish IL-6 expression, suggesting an interaction of these two pathways
in IL-6 induction, most likely at the level of transcriptional regulation and/or mRNA stability.
The p38 and PKC pathways activate multiple transcription factors including CREB, ATF-1,
ATF-2, AP-1, C/EBPβ, and ETS (Buchwalter et al., 2004; Deak et al., 1998; Isakov and Altman,
2002; Kawasaki et al., 1998a; Li et al., 2006; Lim et al., 2005; Morton et al., 2004; Tan et al.,
1996; Togo, 2004; Trautwein et al., 1993). Besides, the promoter region of IL-6 gene contains
several functional binding sites such as CRE, AP-1, C/EBP, and NF-κB (Ammit et al., 2002;
Edwards et al., 2007; Eickelberg et al., 1999; Zhu et al., 1996). Searching for transcription
factors activated by β3AR agonist CL316243, we found that β3AR stimulation leads to
increased expression of reporter constructs containing CRE, but not AP-1, C/EBP, ETS or NF-
κB binding sites, which is in accord with our results from the homogenous reporter assay.
Furthermore, significant increases in phosphorylation of CREB, ATF-1, and ATF-2
transcription factors were observed in response to β3AR-agonist treatment. These transcription
factors belong to a large ATF/CREB family of the basic region-leucine zipper (bZip) proteins
which are defined by their ability to bind to the consensus CRE site (Hai and Hartman,
2001). We next found that pretreatment with a p38 inhibitor remarkably decreased CREB and
ATF-2 phosphorylation, and that pretreatment with a PKC inhibitor diminished ATF-2
activation alone. Overwhelming evidence indicates that ATF/CREB proteins form selective
homo- and heterodimers (De Cesare and Sassone-Corsi, 2000). Thus, it is plausible that
activation of both CREB and ATF-2 transcription factors is required for IL-6 production, and
that these two factors may work synergistically to regulate cytokine expression in adipocytes.
The exact mechanism of their interaction merits further research. Nevertheless, our results
strongly suggest that the CRE site in the IL-6 promoter is the main target for β3AR-induced
transcription, and that this gene activation is mediated by the actions of CREB and ATF-2
transcription factors.
Our findings have important clinical implications. Converging lines of evidence have revealed
that inflammation is a key feature of obesity and type 2 diabetes (Wellen and Hotamisligil,
2005). Although a causal role of IL-6 in diabetes still needs to be clarified, IL-6 levels correlate
with the degree of insulin resistance in human subjects (Bastard et al., 2002; Kern et al.,
2001) and predict the development of type 2 diabetes (Hu et al., 2004; Thorand et al., 2007).
Additionally, circulating levels of IL-6 are elevated in patients with painful inflammatory and
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musculoskeletal conditions (Liebregts et al., 2007). Selective β3AR antagonists have been
shown to reduce circulating levels of IL-6 and corresponding pain behavior in an animal pain
model (Nackley et al., 2005; Nackley et al., 2007). On the other hand, IL-6 plays protective
role improving adenosinergic signaling and increasing neuronal survival under various
pathological conditions (Biber et al., 2008). Furthermore, experiments with hepatectomy and
hepatic warm ischemia/reperfusion injury demonstrated that IL-6 is a critical component for
hepatocyte proliferation and liver regeneration (Camargo et al., 1997; Cressman et al., 1996).
In pursuit of novel therapeutic approaches a series of human β3AR agonists and antagonists
has recently been generated (Brockunier et al., 2001; Candelore et al., 1999; Mathvink et al.,
2000; Parmee et al., 2000). Thus, this work may promote the development of new therapeutic
avenues for the treatment of obesity, inflammatory pain conditions, brain pathology, and liver
diseases.
5. Conclusions
The present work provides novel insights into signal transduction cascades mediating the
β3AR-dependent release of pro-inflammatory cytokine IL-6 in adipocytes. Here, we report that
this IL-6 increase is Gi-independent and doesn’t rely on ERK1/2, PKA, or NF-κB pathways.
Instead, it’s mediated by p38 and PKC signaling through activation of transcription factors
CREB and ATF-2. Elucidation of cellular network regulating IL-6 expression improves our
understanding of molecular mechanisms in obesity, inflammatory pain, and other pathological
conditions where a significant role for IL-6 is implicated.
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β3AR stimulation up-regulates IL-6 production in adipocytes. 3T3-L1 cells treated with the
β3AR-agonist CL316243 (1 μM for 45 min) showed a significant increase in IL-6 mRNA. The
CL316243-induced increase in cytokine transcripts was completely blocked by pre-treatment
with SR59230A (1 μM for 1 h) but not with betaxolol (0.5 μM for 1 h) or ICI118,551 (0.5
μM for 1 h) (a). 3T3-L1 cells treated with the β3AR-agonist CL316243 (1 μM for 24 and 48
h) showed a significant increase in IL-6 protein measured in cell supernatant (b). ***P<0.001
different from untreated.
Tchivileva et al. Page 16














β3AR-induced IL-6 expression is PKA- and Epac-independent. C3H10T1/2 cells were
pretreated with H89 (10 μM for 1 h) prior to stimulation with CL316243 (1 μM for 2 h). The
CL316243-induced activation of the CRE reporter was not inhibited by H89 in the homogenous
reporter assay (a). 3T3-L1 cells were treated with KT5720 (10 μM) or H89 (5-10 μM) for 1 h
prior to treatment with CL316243 (1 μM for 45 min). The CL316243-induced up-regulation
of IL-6 mRNA was not inhibited by KT5720 or H89 (b). Treatment of 3T3-L1 with CTX (100
ng/ml for 4 h) led to increases in IL-6 transcript, while treatment with the Epac agonist 8CPT-2’-
O-Me-cAMP (CPTOMe) (10 μM for 45 min) did not enhance IL-6 expression (c). ***P<0.001
and **P<0.01 different from untreated.
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β3AR-induced IL-6 expression is not mediated by NF-κB pathway. C3H10T1/2 cells were
treated with CL316243 (1 μM) and TNFα (10 ng/ml) for 2 h. In the homogenous reporter assay,
CL316243 didn’t activate the NF-κB reporter, while TNFα did (a). 3T3-L1 cells were pre-
treated with NBD (100 μM) or MG-132 (25-50 μM) for 1 h prior to treatment with CL316243
(1 μM for 45 min). The CL316243-induced up-regulation of IL-6 mRNA was not inhibited by
NBD or MG-132 (b). SEAP activity was assayed from the culture media of HEK 293 cells co-
transfected with the pNF-κB-SEAP reporter construct and β3AR expression vector. No
significant increase in SEAP activity was observed at 6, 12 and 24 h post-treatment with
CL316243 (1 μM) (c). ***P<0.001 and **P<0.01 different from untreated.
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β3AR-induced IL-6 expression is Gi- and ERK1/2-independent and mediated by p38 signaling
pathway. 3T3-L1 cells were pretreated with PTX (100 ng/ml and 200 ng/ml for 1 h) prior to
stimulation with CL316243 (1 μM for 45 min). The CL316243-induced up-regulation of IL-6
transcripts was not blocked by PTX (a). 3T3-L1 cells were pretreated with either U0126 (10
μM) or SB203580 (5-10 μM) for 1 h prior to stimulation with CL316243 (1 μM for 45 min).
The CL316243-induced up-regulation of IL-6 transcripts was blocked by SB203580, but not
U0126 (b). C3H10T1/2 cells were pretreated with SB203580 (10 μM for 1 h) prior to
stimulation with CL316243 (1 μM for 45 min). The CL316243-induced activation of CRE
reporter was inhibited by SB203580 in homogenous reporter assay (c). The cells lysates were
also subjected to Western blot analyses with antibodies to p-p38. Increased phosphorylation
of p38 was observed at 3, 30 and 60 min post-treatment with CL316243. β-actin was used as
the loading control (d). ***P<0.001 and **P<0.01 different from untreated. #P<0.05 different
from CL316243-treated.
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β3AR-induced IL-6 expression is dependent on the PKC signaling pathway. 3T3-L1 cells were
pretreated with RO31-8220 (1-10 μM) for 1 h prior to stimulation with CL316243 (1 μM for
45 min). The CL316243-induced up-regulation of IL-6 transcripts was blocked by RO31-8220
(a). C3H10T1/2 cells were pretreated with RO31-8220 (10 μM for 1 h) prior to stimulation
with CL316243 (1 μM for 2 h). The CL316243-induced activation of CRE reporter was
inhibited by RO31-8220 in the homogenous reporter assay (b). The cells lysates were also
subjected to Western blot analyses with antibodies to pPKCpan (βII Ser660), pPKCα/βII
(Thr638/641), pPKCθ (Thr538), and pPKCε (Ser729). Increased phosphorylation of PKCα/
βII was observed at 30 sec and PKCpan, PKCθ and PKCε 45 min post-treatment with
CL316243. β-actin was used as the loading control (c). ***P<0.001 and **P<0.01 different
from untreated. #P<0.05 different from CL316243-treated.
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Stimulation of β3ARs results in up-regulation of the reporter construct containing the CRE site.
HEK 293 cells were transiently co-transfected with pCRE-SEAP (a), pAP1-SEAP (b), pC/
EBPβ-SEAP (c), or pETS-SEAP (d) reporter constructs along with the β3AR expression vector.
24 h after transfection, media was changed, and cells were stimulated with CL316243 (1 μM)
for 6, 12 and 24 h. Significant increase in SEAP activity was observed with pCRE-SEAP
construct only. ***P<0.001 different from untreated.
Tchivileva et al. Page 21














Effect of β3AR agonist stimulation on phosphorylation of CREB, ATF-1, and ATF-2. 3T3-L1
cells were stimulated with CL316243 (1 μM) for 3, 30, and 60 min, then cell lysates were
subjected to Western blot analyses with antibodies to pCREB, pATF-1, and pATF-2.
CL316243 stimulation increased phosphorylation of pCREB, pATF-1, and pATF-2 (a). 3T3-
L1 cells were pretreated with SB203580 (10 μM for 1h) or RO31-8220 (10 μM for 1 h) before
stimulation with CL316243 (1 μM for 45 min). CL316243-induced phosphorylation of CREB
and ATF-2 was attenuated in the presence of SB203580, while ATF-2 phosphorylation was
also decreased in the presence of RO31-8220, although non-specific phosphorylation of ATF-2
also has been observed in presence of inhibitors alone. ATF-1 phosphorylation was not affected
by inhibitor treatment. β-actin was used as the loading control (b).
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Schematic diagram of the proposed signaling pathways for activation of IL-6 gene by β3AR
stimulation in white adipocytes.
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